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IMPORTANCE The best treatment option for primary vitreoretinal lymphoma (PVRL) without
signs of central nervous system lymphoma (CNSL) involvement determined onmagnetic
resonance imaging or in cerebrospinal fluid is unknown.
OBJECTIVE To evaluate the outcomes of treatment regimens used for PVRL in the prevention
of subsequent CNSL.
DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort studywas conducted at 17
referral ophthalmologic centers in Europe. We reviewed clinical, laboratory, and imaging data
on 78 patients with PVRL who did not have CNSL on presentation between January 1, 1991,
and December 31, 2012, with a focus on the incidence of CNSmanifestations during the
follow-up period.
INTERVENTIONS The term extensive treatmentwas used for various combinations of systemic
and intrathecal chemotherapy, whole-brain radiotherapy, and peripheral blood stem cell
transplantation. Therapy to prevent CNSL included ocular radiotherapy and/or ocular
chemotherapy (group A, 31 patients), extensive systemic treatment (group B, 21 patients),
and a combination of ocular and extensive treatment (group C, 23 patients); 3 patients did
not receive treatment. A total of 40 patients received systemic chemotherapy.
MAIN OUTCOMES ANDMEASURES Development of CNSL following the diagnosis of PVRL
relative to the use or nonuse of systemic chemotherapy and other treatment regimens.
RESULTS Overall, CNSL developed in 28 of 78 patients (36%) at a median follow-up of 49
months. Specifically, CNSL developed in 10 of 31 (32%) in group A, 9 of 21 (43%) in group B,
and 9 of 23 (39%) in group C. The 5-year cumulative survival rate was lower in patients with
CNSL (35% [95% CI, 50% to 86%]) than in patients without CNSL (68% [95% CI, 19% to
51%]; P = .003) and was similar among all treatment groups (P = .10). Adverse systemic
effects occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; themost
common of these effects was acute renal failure.
CONCLUSIONS AND RELEVANCE In the present series of patients with isolated PVRL, the use
of systemic chemotherapy was not proven to prevent CNSL and was associated with more
severe adverse effects compared with local treatment.
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O pinions aredividedonhow to treat primary intraocu-lar lymphoma in the absence of central nervous sys-tem lymphoma (CNSL). Primary intraocular lym-
phoma is anuncommoncancer,manifesting first in the retina
and/or vitreous in 1 or both eyes and is classified as primary
vitreoretinal lymphoma (PVRL).1,2 Primary vitreoretinal lym-
phoma presents predominantly as diffuse, large B-cell lym-
phoma (DLBCL) andhas ahigh associationwithCNSmanifes-
tations and occasionally with testicular manifestations.3-6
Central nervous system lymphoma has been reported1 to de-
velop in approximately 65% to90%ofpatientswithPVRLand
determines thesurvivalof thePVRL-affectedpatients.Theme-
dian overall survival of patients with PVRL is reported7 to be
58 months.
The best therapeutic approach for patients with isolated
PVRL without documented CNS manifestations has not
achieved consensus, particularly because of a paucity of
outcome data. There are 2 distinct approaches to therapy for
patients with isolated PVRL. The first approach consists of
aggressive treatment regimens, such as those used for
CNSL, including high-dose methotrexate-based chemo-
therapy with or without intrathecal treatment and/or whole
brain radiotherapy.8-13 This treatment is aimed at both local
control of PVRL and prevention of subsequent CNSL mani-
festations. The second approach consists of local ocular
treatments. Systemic treatment, such as that used for CNSL,
with intravenous and sometimes intrathecal chemotherapy
may be associated with severe systemic adverse effects;
local ocular treatment, such as ocular radiotherapy and
intravitreal chemotherapy with methotrexate and/or ritux-
imab, lacks systemic adverse effects. The aggressive first
approach to treatment is based on the presumption that the
patients already have developed subclinical lymphoma in
the CNS, which cannot as yet be substantiated by magnetic
resonance imaging or cerebrospinal fluid examination. The
second approach, using local ocular therapy, is aimed at
eradication of lymphoma cells in the eye but has no effect
on possible subclinical manifestations elsewhere. Limited
evidence is available on the efficacy of both approaches. We
retrospectively evaluated the outcomes of diverse treat-
ment regimens used for PVRL in 78 patients from 17 Euro-
pean referral ophthalmologic centers, with a focus on the
incidence of CNS manifestations during the follow-up
period.
Methods
Patients
The studywas conducted in accordancewith the Declaration
ofHelsinki andwas approvedby the institutional ethical com-
mittee of the University Medical Center Utrecht, which con-
cluded that theDutchMedicalResearch InvolvingHumanSub-
jects Act did not apply andwritten informed consent was not
needed. This retrospective study included immunocompe-
tentpatientswithouthumanimmunodeficiencyviruswith iso-
lated PVRL (all classified as DLBCL) between January 1, 1991,
andDecember 31, 2012, from all universitymedical centers as
well as the RotterdamEyeHospital in the Netherlands, Jules-
GoninEyeHospital inSwitzerland,andBristolEyeHospital and
Moorfields Eye Hospital in England, as well as the depart-
ments of ophthalmology fromTübingen andHeidelberg Uni-
versity Hospitals in Germany, Istanbul University in Turkey,
Pitié-SalpêtrièreHospital inFrance,UniversityHospitalofLeón
in Spain, and Centre Hospitalier Universitaire St-Pierre and
Brugmann in Belgium. All data were reviewed for complete-
ness and consistency.
For inclusion into the study, the minimal duration of fol-
low-upneeded to be at least 1 year after the patient’s first pre-
sentation to an ophthalmologist. The lastmonth of follow-up
wasJuly2013.Patientswithprevioussystemic lymphomawere
excluded. Isolated PVRL was diagnosed by ocular tissue bi-
opsy,whereas cerebrospinal fluid examinationand imagingof
the brain were used to exclude CNSL at the time of PVRL di-
agnosis or during the diagnostic process.
We collected clinical data on a total of 104 patients with
PVRL; 26 of these patients were excluded (17 because the di-
agnosis of PVRLwas confirmedwhenCNSmanifestationshad
alreadydeveloped and9because of insufficient data). The re-
maining 78 patients were included in our analysis (Table 1).
The following data were collected: age, sex, date of onset
of ocular symptoms, date of diagnosis of PVRL, type and date
of treatment, all relevant ocular and systemic treatment com-
plications,dateofPVRLrelapse,dateofmanifestationofCNSL,
survival (years), and cause of death. The term extensive treat-
ment was used for various combinations of systemic and in-
trathecal chemotherapy, whole-brain radiotherapy, and pe-
ripheral blood stem cell transplantation.
Statistical Analysis
The primary outcome of this retrospective study was the de-
velopment of CNSL and its association with the type of PVRL
treatment used. Secondary end points were relapse of PVRL,
survival, and cause of death. The data were analyzed using
SPSS, version 20 (SPSS Inc).
Differences in thedistributionof individual featuresamong
treatment groups were analyzed by means of the χ2 test or
Fisher exact test for categorical variables and the Mann-
Whitney test or Kruskal-Wallis test for continuous, nonpara-
metric variables. Survival was defined as the time from first
symptoms of PVRL to death or CNSL, or the time to the last
follow-upassessment. Survival rateswerecalculatedusing the
Kaplan-Meier method, and differences were compared with
the use of the log-rank test.
Results
Patient Characteristics
The patient characteristics are reported in Table 1. The me-
dian age at the time of PVRL diagnosis was 58 years (range,
39-86 years) and 34 of 78 patients (44%) weremale. At onset,
PVRLwas bilateral in 45 (58%) patients. Themedian duration
from symptom onset to diagnosis of PVRL was 10 months
(range, 0-63months). Thediagnosis of isolatedPVRLwas con-
firmed by ocular tissue biopsy in all 78 patients. The median
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follow-up timeafter the first presentation to theophthalmolo-
gist was 49 months (range, 15-246 months).
Of all 78 patients, 28 individuals (36%) subsequently de-
veloped CNSL and 23 (29%) patients died during the fol-
low-up period. Patients with and those without CNSL mani-
festations were similar in male to female ratio and bilateral
occurrenceofPVRL (P = .34andP = .94, respectively).Agewas
similar between the patients who developed CNSL and those
whodidnotdevelopCNSL (median age, 65 years; range, 41-86
years [95%CI, 60.1-65.6]; vs 59 years; range, 39-80 years [95%
CI, 53.5-61.1];P = .15). The follow-up time from first presenta-
tion to the ophthalmologist of patients with CNSL and those
withoutCNSLwasalsosimilar (median74months; range,9-122
months [95%CI,49.3-76.5]; vs42months; range, 3-246months
[95% CI, 49.1-73.4]; P = .34). The CNSL manifestations were
similar in patients includedbefore 2005 comparedwith those
included after 2005 (P = .28).
Therapeutic Approaches
Treatment regimenswere principally classified into 3 catego-
ries: ocular radiotherapy and/or ocular chemotherapy (group
A), extensive systemic treatment (group B), and a combina-
tion of ocular and extensive systemic treatment (group C).
Three additional patients did not receive treatment (Table 2).
Ocular treatment included local radiotherapy and intra-
vitreal application of methotrexate sodium and/or ritux-
imab. Extensive treatment regimens are listed in Table 2 and
consisted of combinations of different regimens of systemic
and intrathecal chemotherapy (n = 40), whole-brain radio-
therapy (n = 6), and peripheral blood stem cell transplan-
tation (n = 4). Intrathecal treatment was always given in
combination with intravenous treatment. CHOP (cyclo-
phosphamide, hydroxydaunorubicin, Oncovin [vincristine],
and prednisone) chemotherapy was not considered sys-
temic treatment because it is not effective for CNSL
(Table 2).15-17
The patient characteristics per treatment group are sum-
marized in Table 1. Of the 78 included patients 31 individuals
(40%) received only ocular treatment. These patients re-
ceivedradiotherapy(16[52%]), intravitrealmethotrexateand/or
rituximab (12 [39%]), or a combinationof radiotherapy and in-
travitreal chemotherapy (2 [6%]); 1 (3%)of the 31 affected eyes
was enucleated. Additionally, 3 (4%) patients did not receive
treatment initially forPVRL,owing to thepreferenceof thepa-
tient (n = 2) or physician (n = 1).
Patient Characteristics in Specific Treatment Groups
The 3 treatment groups were similar in diverse variables
including sex (P = .54), age (P = .07), duration from the onset
of symptoms to diagnosis of PVRL (P = .65), interval from
the first presentation of PVRL to the ophthalmologist to the
onset of CNSL (P = .50), and duration of follow-up (P = .24).
Furthermore, the duration of follow-up was similar for
patients receiving ocular radiotherapy and chemotherapy
(P = .18).
Effect of PVRL Treatment on CNSLManifestations
Central nervous system lymphoma developed in 28 of 78 pa-
tients (36%): 10 (32%) patients in group A, 9 (43%) in group B,
and9 (39%) in groupC (P = .76) (Table 1). Similar rates of CNSL
manifestations were observed when group A was compared
with solely systemic chemotherapy and when group A was
compared with group B (P = .53 and P = .45, respectively). In
addition, development of CNSLmanifestationswas similar in
patientswho receivedocular chemotherapy andocular radio-
therapy (P = .23).Whenpatients receiving intrathecal therapy
were not included in the extensive treatment group, the re-
sults of development of CNS manifestations did not change.
Central nervous system lymphoma developed in 14 of 30 pa-
tients (47%) who received 6 courses of intravenous metho-
trexate and 4 of 14 (28%) patients receiving other extensive
treatment modalities.
Table 1. Patient Demographics and Clinical Characteristics
Characteristic
All Cases
(N = 78)
No Treatment
(n = 3)
Group Aa
(n = 31)
Group Bb
(n = 21)
Group Cc
(n = 23)
Age, median (range), y 58 (39-86) 81 (55-83) 65 (41-86) 59 (43-73) 62 (39-83)
Male sex, No. (%) 34 (44) 2 (67) 12 (39) 8 (38) 12 (52)
Interval between onset of symptoms to diagnosis,
median (range), mo
10 (0-63) 11 (9-19) 10 (1-42) 10 (2-41) 7 (0-63)
Bilateral PVRL, No. (%) 45 (58) 3 (100) 14 (45) 12 (57) 16 (70)
CNSL development, No. (%) 28 (36) 0 10 (32) 9 (43) 9 (39)
Interval between first manifestations of PVRL and
CNSL, median (range), mo
29 (7-133) Not available 28 (7-66) 29 (20-133) 46 (11-126)
Recurrence of vitreoretinal lymphoma during
follow-up, No. (%)
17 (22) 0 4 (13) 6 (29) 7 (30)
Follow-up from first presentation to
ophthalmologist, median (range), mo
49 (15-246) 34 (17-119) 48 (15-260) 44 (17-133) 78 (17-133)
Abbreviations: CNSL, central nervous system lymphoma; PVRL, primary
vitreoretinal lymphoma.
a Included patients who received only ocular treatment; 2 patients also received
CHOP (cyclophosphamide, hydroxydaunorubicin, Oncovin [vincristine], and
prednisone), but this was not considered systemic treatment because it is not
effective for CNSL.
b Included patients who received extensive systemic treatment.
c Included patients who received a combination of ocular and extensive
treatment.
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Kaplan-Meier 10-year survival curves (calculated fromthe
first presentation with PVRL symptoms to the ophthalmolo-
gist to the development of CNS manifestations) were similar
whenthe3treatmentgroupswerecompared(P = .91) (Figure1).
Similar outcomes were observed between the specific treat-
ment groups (ocular treatment only vs extensive treatment
only, P = .96; ocular treatment only vs a combination of ex-
tensive and ocular treatment, P = .56; and extensive treat-
ment only vs a combination of systemic chemotherapy and
ocular treatment, P = .80).
Ocular Relapse of PVRL
Ocular relapse of PVRL occurred in 17 of 78 patients (22%)
within 12 to 131months after the first symptomsof PVRL (95%
CI, 24.9 to 66.7; median, 28 months). The risk of ocular re-
lapsewassimilaramongthespecific treatmentgroups (P = .53).
The incidence of ocular relapse in patients in groupAwas not
significantly different from that inpatientswho receivedonly
systemic chemotherapy (P = .31). A similar incidence of ocu-
lar relapse also was observed between patients who received
solely ocular chemotherapy and those who underwent ocu-
lar radiotherapy (P = .60).
Treatment Complications
Systemic chemotherapywasused in40patients (51%) (23who
weregivenextensivetreatmentonlyand17whoreceivedacom-
binationofocular andextensive treatment).Oneormore com-
plicationsdeveloped in9of40(23%)patientswhoreceivedsys-
temic chemotherapy (eTable 1 in the Supplement) with acute
renal failure being themost common (4 [10%]). Ocular radio-
therapy was administered in 34 eyes. One or more complica-
tions occurred in 10 of these patients (29%) (eTable 1 in the
Supplement). Intravitrealchemotherapywasgivento19patients
and complications developed in 5 of these individuals (26%)
(eTable1 intheSupplement).Radiotherapy-associatedencepha-
lopathydidnotdevelop inpatientswho received treatment for
PVRLwith whole-brain radiotherapy (n = 6) during amedian
follow-up time of 46months (range, 3-134months).
Table 2. Types of Treatment Given for Primary Vitreoretinal Lymphoma
in 78 Patients
Type of Treatment
Patients,
No. (%)
No treatment 3 (4)
Group Aa 31 (40)
Ocular radiotherapy 16 (52)
Intravitreal methotrexate sodium and/or rituximab 12 (39)
Intravitreal methotrexate 9 (29)
Intravitreal rituximab 2 (6)
Intravitreal methotrexate and rituximab 1 (3)
Ocular radiotherapy and intravitreal chemotherapy 2 (6)
Enucleation 1 (3)
Group Bb 21 (27)
Group Cc 23 (29)
Intravitreal and intravenous chemotherapy 4 (17)
Intravitreal and intrathecal chemotherapy 1 (4)
Intravitreal and intravenous chemotherapy, cerebral
radiotherapy
1 (4)
Intravitreal and intravenous chemotherapy, PBSCT 1 (4)
Ocular radiotherapy, intravenous chemotherapy 6 (26)
Ocular radiotherapy, intrathecal chemotherapy 3 (13)
Ocular and cerebral radiotherapy 2 (9)
Ocular radiotherapy, intravenous and intrathecal
chemotherapy
2 (9)
Ocular and cerebral radiotherapy, intravenous
chemotherapy
2 (9)
Ocular and cerebral radiotherapy, intravenous and
intrathecal chemotherapy
1 (4)
Intravenous treatment 40 (51)
CHOP 2 (5)
High-dose methotrexate based 16 (40)
Cytarabine based 4 (10)
Methotrexate and cytarabine 5 (13)
Rituximab 1 (3)
Rituximab and cytarabine 2 (5)
Rituximab, methotrexate, and cytarabine 3 (8)
Rituximab, methotrexate, cytarabine, and PBSCT 4 (10)
COPADEM protocold 3 (8)
Intrathecal treatment 10 (13)
Methotrexate 7 (70)
Methotrexate and cytarabine 3 (30)
Cerebral treatment 6 (8)
Radiotherapy 6 (100)
Abbreviations: CHOP, cyclophosphamide, hydroxydaunorubicin, Oncovin
(vincristine), and prednisone; CNS, central nervous system; COPADEM,
cyclophosphamide, vincristine, prednisolone, doxorubicin, hydrocortisone, folic
acid, andmethotrexate; PBSCT, peripheral blood stem cell transplantation.
a The ocular treatment group included 2 patients who also received CHOP and
were considered as not receiving systemic treatment.
b Extensive treatment only.
c Combination of ocular and extensive treatment.
dReported in the study of Blay et al.14
Figure 1. Kaplan-Meier 10-Year Survival Estimates in 78 Patients
With Primary Vitreoretinal Lymphoma (PVRL)
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Central nervous system lymphomawas the outcome. Survival estimates did not
differ significantly between the treatment groups (P = .91).
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Cause of Death
Of78patients, 23 individuals (29%)died; 7 (30%)patients from
CNSL, 3 (13%) from indirect complications of CNSL, including
complications of treatment, and 3 (13%) patients died of lym-
phoma-unrelated causes. Data were not available on 10 pa-
tients. The death rates between the 3 treatment groups (un-
treated patients were not included) were similar (P = .07).
Central nervous system lymphomawashighlyassociatedwith
death (14 of 28 patients [50%]whodeveloped CNSL vs 9 of 50
patients [18%]whodidnotdevelopCNSL;P = .003).Thecauses
of death per treatment group are displayed in eTable 2 in the
Supplement.
Overall Survival and Progression-Free Survival
Themedianoverall survival frompresentation to theophthal-
mologist with PVRL until death was 44months (range, 11-113
months) inpatientswhodidnotdevelopCNSLand34months
(range, 12-131 months) in patients who developed CNSL (95%
CI, −32.9 to 58.7; P = .43). The 5-year cumulative survival rate
was lower in patients with CNSL (35% [95% CI, 50% to 86%])
than in patients without CNSL (68% [95% CI, 19% to 51%];
P = .003) (Figure 2A) and was similar among all treatment
groups (P = .10) (Figure2B).ThemedianCNSL-freesurvivalwas
47months (95%CI, 46.8 to61.8; range, 7-152months) in all pa-
tients who received treatment. Overall and progression-free
survival were similar among the 3 treatment groups (P = .74
and P = .15, respectively).
Discussion
Our study illustrates the lack of a consistent treatment ap-
proach for patients with PVRL, and the data provide current
outcomes of a similar prevalence of CNSL manifestations
amongpatientswithPVRL treatedwithvariousocular andex-
tensive treatment regimens. Inour retrospectivestudytheben-
efit of extensive treatment strategies in patients with PVRL
without CNS involvement couldnot be substantiated in ame-
dian follow-up duration of 49 months.
Toourknowledge, thepresent study represents oneof the
largest contemporary series onPVRLoutcomes and is particu-
larlypertinentbecause itpresents ahomogeneousgroupofpa-
tients with PVRLwithout signs of CNS involvement. The pre-
viously reported1 prevalenceofCNSL (60%-95%) secondary to
PVRLappears tobehigher thanthat in thepresentseries,which
might in part be explained by the fact that our study ex-
cluded all patients with positive cerebrospinal fluid findings
as well as patients in whom the diagnosis of PVRL was con-
firmed after CNSL had developed. Inclusion of these patients
would have biased the study toward a higher frequency of
CNSL. Grimm et al7 conducted a retrospective study includ-
ing83patientswithPVRLfrom16centers in7countries. Incon-
trast to our study, the classification of PVRL in their series in-
cluded 11 patients with cerebrospinal fluid that contained
lymphoma cells. Furthermore, the median follow-up in the
studybyGrimmet alwas 32months andnominimal duration
of follow-upwasusedasan inclusioncriterion. In linewithour
findings, initial treatment regimens in the study by Grimmet
al varied widely and consisted of local therapy in 28% of the
patients (which included ocular radiotherapy and chemo-
therapy), extensive therapy in 64% of the patients (systemic
chemotherapy and whole brain radiotherapy), and no treat-
ment in 7% of the patients. Central nervous system lym-
phomadeveloped in47%of all includedpatients in theGrimm
et al series and local therapy without systemic treatment or
brain radiotherapy did not increase the risk of brain relapse
comparedwith an intensive treatment regimen (P = .4). These
results are in accordance with our findings and indicate that
ocular treatment of PVRL was not associated with an excess
of CNS manifestations compared with more aggressive (sys-
Figure 2. Kaplan-Meier 5-Year Overall Survival for Primary Vitreoretinal Lymphoma (PVRL)
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A, Patients who developed central nervous system lymphoma (CNSL) and patients who did not develop CNSL (P = .003). B, Overall survival estimates following
treatment for PVRL by treatment group (P = .10).
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temic) treatment regimens.Furthermore,ourpatientswere se-
lected from ophthalmology departments rather than neuro-
oncology departments as in the series by Grimm et al,
eliminating possible selection bias in favor of CNSL develop-
ment. Most published studies8,18,19 on local PVRL treatment
focus on its effect on PVRL and do not have sufficient fol-
low-up data to report on the incidence of subsequent CNS
manifestations.
Of thepatients in thepresent studywhoreceivedonlyocu-
lar radiotherapy, 29%developedadverseeffects.However, our
series included patients from 1991 onward. In the early 1990s
radiotherapy treatment regimens differed in intensity com-
paredwithmore recent strategies.20 At present, radiotherapy
is of lower intensity (36 Gy), therapy is fractionated, and al-
though dry eyes during treatment and cataract after radio-
therapy develop regularly, retinopathy is uncommon.20,21
Teckie and Yahalom19 indicated in their series that no serious
adverse effects of radiotherapy developed and countered the
claim that permanent visual loss might occur.
More recently, intraocular chemotherapyhasgainedpopu-
larity and includes diverse regimens of methotrexate and ri-
tuximab.Adverse effects of administrationof these agents oc-
cur only within the eye and include hyperemia, keratopathy,
cataract, glaucoma, iridocyclitis, vitreous hemorrhage, reti-
naldetachment,maculopathy, andendophthalmitis.22-25 Proof
of superiority of intraocular chemotherapy vs radiotherapy is
lacking because no comparative studies have been per-
formed. The advantages of local chemotherapy over intrave-
nous treatment are higher levels of chemotherapeutic agents
in the eye and the lack of systemic, possibly life-threatening,
adverse effects.
To date, the pathogenesis of VRLwith CNSL is not known
andthemechanismof itsoriginandsubsequentmetastasishas
not been elucidated. It is not knownwhether CNS and ocular
manifestations occur independently or whether this type of
lymphoma originates at one site, subsequently spreading to
other sites. Our results, as well as the frequent bilateral in-
volvement in VRL and the long intervals betweenmanifesta-
tions of large B-cell lymphoma at different immune-
privileged sites, favor the possibility of a multifocal origin.26
In addition, spreading from one site to others might concur-
rently develop. Themultifocal origin of lymphoma at various
immune-privileged sites has been ascribed27 to an ineffective
immune response to lymphoma cells at these protected sites.
Boomanet al28 studied thegenomic alterationofDLBCLof the
testes and CNSL and showed that DLBCL in these 2 locations
exhibits both sharedandsite-specific genetic alterations.They
concluded that these findings underline the concept of im-
mune-privileged site lymphomabut that CNS and testes lym-
phoma do not form a single entity.
Our study has the shortcomings of a retrospective de-
sign. The reasoning for the choice of treatment in individual
patients couldnot bedetermined.However thedifferent hos-
pitals tended to use the same treatment modalities for all of
their patients. Because the patient characteristics did not dif-
fer significantly between treatment groups and the choice of
treatmentwasbasedprimarilyonwhich treatmentoptionwas
conventional per treatment center, the bias seems to be lim-
ited. Survival analysis of the 3 treatment subgroups showed a
possible trend in favorofpatientswhoreceivedextensive treat-
ment and an analysis using a larger series may disclose con-
clusions that differ from the current data. The log-rank of this
Kaplan-Meier 10-year survival curve was similar when the 3
treatment groupswere compared; however, the proportional
hazard assumption was not met, and therefore the log-rank
wasbiased. Inour study, the rateof local recurrenceswas simi-
lar for local and systemic treatment regimens. The intrave-
nouschemotherapyregimensdifferedwidelyand illustrate the
lack of a systematic approach even within this treatment ap-
proach. Peripheral blood stemcell transplantationhas shown
promising results,29-31 but thenumber of patients in our study
was too limited to evaluate this treatment. Our results relate
to the group as a whole and do not exclude a possible benefi-
cial effect of a specific treatment strategy, which emphasizes
the need for international cooperation and prospective
studies.
Conclusions
The development of CNS manifestations after PVRL in our
studywassimilar inpatientswithPVRLwhoreceived localocu-
lar treatments compared with patients who received sys-
temic treatments. Specific regimens, such asperipheral blood
stem cell transplantation and novel chemotherapies, should
besystematicallyanalyzedbecause these regimensmighthave
greater value than local treatment. In the present series, the
additional benefit of systemic chemotherapy could not be
provenandwas associatedwith a greater number of andmore
severe adverse effects compared with local therapy.
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